{{'Search' | translate}}
 

TrypLETM Express Enzyme (1X), phenol red

Company: Thermo Fisher Scientific
Catalog#: 12605093
Bio-protocol()
Company-protocol()
Other protocol()

In vitro Co-culture of Mesenchymal Stem Cells and Endothelial Colony Forming Cells
Author:
Date:
2017-10-20
[Abstract]  The discovery of endothelial colony forming cells (ECFCs) with robust self-renewal and de novo vessel formation potentials suggests that ECFCs can be an excellent cell source for cardiovascular diseases treatment through improving neovascularization in the ischemic tissues. However, their engraftment after transplantation resulted to be low. Previous studies showed mesenchymal stem/stromal cells (MSCs) could improve the survival and capillary formation capacity of ECFCs in co-culture systems. In this article, we describe a protocol for in vitro co-culture of MSCs and ECFCs to prime ECFCs for better engraftment. [摘要]  发现具有强大自我更新和从头血管形成潜力的内皮细胞集落形成细胞(ECFCs)表明,ECFC可以通过改善缺血组织的新生血管形成,成为心血管疾病治疗的优良细胞来源。 然而,移植后的移植导致了低位移植。 以前的研究显示间充质干/基质细胞(MSC)可以改善共培养系统中ECFCs的存活和毛细管形成能力。 在这篇文章中,我们描述了体外协调MSCs和ECFCs共同培养ECFC以实现更好的移植。
【背景】内皮祖细胞(EPC)被定义为能够通过血管发生过程形成新血管的细胞群。 2004年,Ingram等人鉴定了来自人脐带血的称为“内皮细胞集落形成细胞(ECFC)”的离体培养物中的特异性高度增殖的EPC群体Ingram等人,2004),并且这些细胞最近被宣布代表EPCs(Medina等人,2017)。类似的群体也可以从具有等效血管化潜力和临床相关数量的人类胎盘组织中分离(Patel等人,2013; Shafiee等人,2015) )。因此,ECFC移植已被提出作为缺血性疾病如心肌梗塞或关键性腿部缺血的治疗方法。然而,移植后的ECFCs植入物和血管生成潜力被证明是低的(Shafiee等人,2017; ...

Comments